ArticleQuantitative imaging in medicine and surgery2026
Combined hematology, tumor morphology, and magnetic resonance imaging for predicting microvascular invasion in hepatocellular carcinoma: a clinical study.
Article in Quantitative imaging in medicine and surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Non-Invasive Assessment of Microvascular Invasion Risk in Hepatocellular Carcinoma Using Liquid Biopsy: Translational Insights and Clinical Implications.Diagnostics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Microvascular invasion (MVI) is an independent risk factor for postoperative recurrence in hepatocellular carcinoma (HCC), making preoperative prediction clinically critical. This study aimed to identify factors associated with MVI and develop a clinically applicable predictive model using patient-derived variables, including serological markers, tumor morphology, and magnetic resonance imaging (MRI) features. Methods: A retrospective analysis was conducted on 236 patients with HCC who underwent surgical resection between January 1, 2019, and December 31, 2022, at the Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Hospital of Guangdong Medical University. Patients were randomly assigned to training and validation cohorts at a 1:1 ratio. Significant factors identified through univariate analysis with P values adjusted via the Benjamini-Hochberg method (adjusted P<0.05) were subjected to binary logistic regression to determine the independent risk factors for MVI in HCC. These factors were used to develop a nomogram for MVI prediction, with its diagnostic performance assessed through receiver operating characteristic (ROC) curves. Additionally, k-fold cross-validation (k=5) was performed to evaluate model stability. Results: There were 236 patients included, with 118 in each cohort. Logistic regression identified four independent risk factors for MVI: arterial phase edge enhancement [odds ratio (OR) =4.610, P=0.011], incomplete tumor capsule (OR =4.513, P=0.013), alpha-fetoprotein (AFP) >800 ng/mL (OR =3.407, P=0.035), and intratumoral vascular enhancement (OR =6.300, P=0.022). In the training cohort, the area under the curve (AUC), sensitivity, specificity and Youden index (YI) of the nomogram were 0.871 (P<0.001), 78.8%, 80.0% and 0.645, respectively; while in the validation cohort, they were 0.878 (P<0.001), 83.9%, 86.2% and 0.689, respectively, with both cohorts' AUC results consistent with the average AUC of 0.860 from k-fold cross-validation. Decision curve analysis and calibration curve results confirmed high model accuracy and clinical benefit. Conclusions: AFP >800 ng/mL, intratumoral vascular enhancement, arterial phase enhancement, and incomplete tumor capsule are independent risk factors for MVI in HCC. Combining serological, morphological, and MRI characteristics offers robust utility and accuracy in predicting MVI in HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.